High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

[1]  A. Barać,et al.  COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) , 2021, Journal of Hematology & Oncology.

[2]  S. Kerr,et al.  Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries , 2021, Scientific Reports.

[3]  M. Beksac,et al.  Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies , 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[4]  T. Zewotir,et al.  Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients , 2021, BMC Infectious Diseases.

[5]  M. Ellis,et al.  COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome , 2021, Leukemia & lymphoma.

[6]  M. Diercke,et al.  Die verschiedenen Phasen der COVID-19-Pandemie in Deutschland: Eine deskriptive Analyse von Januar 2020 bis Februar 2021 , 2021, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[7]  W. Haas,et al.  Die verschiedenen Phasen der COVID-19-Pandemie in Deutschland: Eine deskriptive Analyse von Januar 2020 bis Februar 2021 , 2021, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[8]  R. Balusu,et al.  Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients , 2021, Transplantation and Cellular Therapy.

[9]  Christine S. Smedley,et al.  Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study , 2021, The Lancet Global Health.

[10]  G. Shefer,et al.  Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study , 2021, Transplantation and Cellular Therapy.

[11]  N. Kröger,et al.  COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey , 2021, Leukemia.

[12]  M. Christner,et al.  Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020 , 2021, Journal of clinical medicine.

[13]  A. Nordström,et al.  Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study , 2021, European Journal of Epidemiology.

[14]  M. Robin,et al.  Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort study , 2021, British Journal of Haematology.

[15]  M. Perales,et al.  Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study , 2021, The Lancet Haematology.

[16]  COVID-ICU Investigators.  Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study , 2021 .

[17]  F. Moreso,et al.  COVID-19 in transplant recipients: The Spanish experience , 2020, American Journal of Transplantation.

[18]  G. Maudsley,et al.  Age-Adjusted Associations Between Comorbidity and Outcomes of COVID-19: A Review of the Evidence From the Early Stages of the Pandemic , 2020, Frontiers in Public Health.

[19]  A. Ciavarella,et al.  Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy , 2020, Infectious diseases.

[20]  S. Pedraza-Sánchez,et al.  Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease: A pilot study , 2020, Journal of internal medicine.

[21]  J. Masjuán,et al.  The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19 , 2020, Journal of Clinical Immunology.

[22]  M. Diercke,et al.  Krankheitsschwere der ersten COVID-19-Welle in Deutschland basierend auf den Meldungen gemäß Infektionsschutzgesetz , 2020 .

[23]  Aasith Villavicencio,et al.  COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature , 2020, Transplantation Reviews.

[24]  J. Pell,et al.  Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants , 2020, PloS one.

[25]  H. Ohtsu,et al.  First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics , 2020, Journal of Infection.

[26]  W. Wood,et al.  Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.

[27]  P. Guisado-Vasco,et al.  Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort) , 2020, EClinicalMedicine.

[28]  N. E. Babady,et al.  Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. , 2020, The Journal of clinical investigation.

[29]  A. Ganser,et al.  Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. , 2020, The Journal of infectious diseases.

[30]  E. Daugas,et al.  COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. , 2020, Journal of the American Society of Nephrology : JASN.

[31]  C. Solano,et al.  Risk factors and outcome of COVID-19 in patients with hematological malignancies , 2020, Experimental Hematology & Oncology.

[32]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[33]  J. Borghi,et al.  Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes , 2020, Journal of medical virology.

[34]  A. Testro,et al.  Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis , 2020, Transplantation Proceedings.

[35]  R. Busse,et al.  Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study , 2020, The Lancet Respiratory Medicine.

[36]  M. Cescon,et al.  COVID‐19 in solid organ transplant recipients: No difference in survival compared to general population , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[37]  S. Nahavandi,et al.  Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients , 2020, medRxiv.

[38]  A. Agarwal,et al.  Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review , 2020, PloS one.

[39]  C. Mantzoros,et al.  Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York , 2020, Metabolism.

[40]  C. Mantzoros,et al.  Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York , 2020, Metabolism.

[41]  N. Uriel,et al.  COVID-19 in solid organ transplant recipients: Initial report from the US epicenter , 2020, American Journal of Transplantation.

[42]  G. Lippi,et al.  Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection , 2020, International Urology and Nephrology.

[43]  S. Montoto,et al.  The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus , 2020, Bone Marrow Transplantation.

[44]  P. Bardy,et al.  Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation: Respiratory viruses causes late morbidity post-HSCT. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  V. Vinuesa,et al.  Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[46]  T. Tanaka,et al.  Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation , 2016, Bone Marrow Transplantation.

[47]  M. Boeckh,et al.  Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. , 2001, Blood.

[48]  P. Ljungman.  Respiratory virus infections in bone marrow transplant recipients: the European perspective. , 1997, The American journal of medicine.